NCT02711969View on ClinicalTrials.gov

A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

November 30, 2016

Study Completion Date

March 31, 2019

Conditions
Gastric Cancer
Interventions
DRUG

Apatinib mesylate

1,000mg Apatinib mesylate p.o. qd

Trial Locations (1)

Unknown

Asan medical center, Seoul

Sponsors
All Listed Sponsors
lead

Bukwang Pharmaceutical

INDUSTRY

NCT02711969 - A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment | Biotech Hunter | Biotech Hunter